Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
INmune Bio Inc. is a clinical stage biotechnology company that is developing new i...
INmune Bio Inc. is a clinical stage biotechnolo...
Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing ...
Trillium Therapeutics Inc. is a clinical stage ...
ILLUSIO is a plastic surgery simulation tool that enables a surgeon and patient to...
ILLUSIO is a plastic surgery simulation tool th...
AVROBIO, Inc., a leader in lentiviral-based gene therapies, is a clinical stage co...
AVROBIO, Inc., a leader in lentiviral-based gen...
Allogene Therapeutics is a clinical stage biotechnology company pioneering the dev...
Allogene Therapeutics is a clinical stage biote...
Apollo Endosurgery, Inc. is a medical device company focused on less invasive ther...
Apollo Endosurgery, Inc. is a medical device co...
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on the deve...
Pacira BioSciences, Inc. is a specialty pharmac...
Join the National Investor Network and get the latest information with your interests in mind.